LMS CALM® RECEIVES HIGH CUSTOMER SATISFACTION SCORES IN THE 2008 KLAS LABOR AND DELIVERY REPORT

Click here for the PDF version of this release
Click to return to Press Releases

Montreal, Quebec, April 30, 2008 – LMS Medical Systems (AMEX:LMZ; TSX:LMZ), a healthcare technology company and developer of the CALM patient safety software system for obstetrics is pleased to announce receiving a score of 88.8 in the KLAS 2008 Labor and Delivery report, read by the healthcare IT industry. LMS met the criteria to be included in the early data section of the report and is pleased to have received the highest performance score among all applications included in the report.

The prestigious and independent analysis of healthcare software by KLAS featured an extensive report on Labor and Delivery (L&D) solutions in March 2008. Key evaluation criteria included the integration with hospital wide information systems, the range of functionality most important to health care providers, and client satisfaction with vendor software offerings and support services.

“Our main objective with the CALM software has been to improve the safety of childbirth for mothers and their infants. We have done this first by developing advanced risk assessment tools, second by imbedding these tools in software that is practical and easy to use for clinicians who take care of patients and third, by offering stellar service and training,” says Dr. Emily Hamilton, founder and Vice President Medical Research. “We are thrilled that our customers are recognizing this and rewarding us with this performance scoring in the industry’s most important and comprehensive evaluations.”

The report is available through KLAS.

About LMS
LMS is a leader in the application of advanced mathematical modeling and neural networks for
medical use. The LMS CALM Suite provides physicians, nursing staff, risk managers and
hospital administrators with clinical information systems and risk management tools designed to
improve outcomes and patient care for mothers and their infants during childbirth.

About KLAS
KLAS is a research firm that specializes in monitoring and reporting the performance of
healthcare’s information technology (HIT) vendors. KLAS’ mission is to improve HIT delivery
by independently measuring vendor performance for the benefit of our healthcare provider
partners, consultants, investors, and vendors. Working together with executives from over 4500
hospitals and over 2500 clinics, KLAS delivers timely reports, trends, and statistics, which
provide a solid overview of vendor performance in the HIT industry. KLAS measures
performance of software, professional services, and medical equipment vendors. For more
information, go to www.KLASresearch.com, email marketing@KLASresearch.com, or call 1-
800-920-4109 to speak with a KLAS representative.

Except for historical information contained herein, the matters discussed in this news release are forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed implied by the forward-looking statements including, but without limitation, economic conditions in general and in the healthcare market, the demand for and market for our products in domestic and international markets, our current dependence on the CALM product suite, the challenges associated with developing new products and obtaining regulatory approvals if necessary, research and development activities, the uncertainty of acceptance of our products by the medical community, the lengthy sales cycle for our products, third party reimbursement, competition in our markets, including the potential introduction of competitive products by others, our dependence on our distributors, physician training, enforceability and the costs of enforcement of our patents, potential infringements of our patents and the other factors set forth from time to time in the Company’s filings with the United States Securities and Exchange Commission and with the Canadian Securities Commissions. The Company has no intention of or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.